AS

Amber Salzman

CEO

Epicrispr Biotechnologies


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Epicrispr Biotechnologies
Industry
research
Employees
41.0
Seniority
C suite
Annual Revenue
1000000.0
Total Funding
55000000.0
Latest Funding
Series A

Technologies

Gmail Google Apps Microsoft Office 365 Greenhouse.io Google Cloud Hosting Google Tag Manager Gravity Forms WordPress.org MailChimp Nginx reCAPTCHA Vimeo Mobile Friendly Remote

Keywords

biotechnology research epigenetic therapy genetic medicine gene modulation customized therapies gene expression epigenome editing crispr technology gene expression modulation system gems platform gene silencing dna-binding proteins guide rnas modulator proteins transcriptional activators transcriptional repressors epigenomic modulators mutation-agnostic therapeutic targets in vivo delivery ex vivo delivery neuromuscular diseases d4z4 methylation facioscapulohumeral muscular dystrophy clinical trials fda clearance biotechnology crispr-cas9 epigenetic editing gene therapy gene regulation molecular biology synthetic biology transcription factors chromatin remodeling gene therapy for rare diseases dcas9 pathogenics precision medicine genome engineering epigenetic biomarkers novel therapies biotherapeutics nuclease-deactivated cas9 therapeutic pipeline next-generation car-t cells protein engineering data science in biotech computational genomics genomic therapies bioengineering advancements health care health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans